News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
692,037 Results
Type
Article (39532)
Company Profile (288)
Press Release (652217)
Section
Business (204781)
Career Advice (2006)
Deals (35493)
Drug Delivery (91)
Drug Development (81187)
Employer Resources (170)
FDA (16195)
Job Trends (14881)
News (346228)
Policy (32649)
Tag
Academia (2547)
Alliances (49503)
Alzheimer's disease (1264)
Approvals (16146)
Artificial intelligence (146)
Bankruptcy (352)
Best Places to Work (11643)
Biotechnology (204)
Breast cancer (188)
Cancer (1368)
Cardiovascular disease (110)
Career advice (1673)
Cell therapy (281)
Clinical research (64951)
Collaboration (484)
Compensation (260)
COVID-19 (2547)
C-suite (108)
Data (1392)
Diabetes (174)
Diagnostics (6222)
Earnings (85051)
Employer resources (148)
Events (110746)
Executive appointments (394)
FDA (16867)
Funding (427)
Gene therapy (196)
GLP-1 (603)
Government (4360)
Healthcare (18805)
Infectious disease (2639)
Inflammatory bowel disease (111)
Interviews (310)
IPO (16392)
Job creations (3636)
Job search strategy (1426)
Layoffs (418)
Legal (7899)
Lung cancer (197)
Lymphoma (98)
Manufacturing (207)
Medical device (13344)
Medtech (13349)
Mergers & acquisitions (19263)
Metabolic disorders (456)
Neuroscience (1585)
NextGen Class of 2024 (6537)
Non-profit (4486)
Northern California (1696)
Obesity (261)
Opinion (183)
Patents (117)
People (56771)
Phase I (20211)
Phase II (28610)
Phase III (21300)
Pipeline (514)
Postmarket research (2570)
Preclinical (8602)
Radiopharmaceuticals (237)
Rare diseases (259)
Real estate (5928)
Regulatory (21800)
Research institute (2327)
Resumes & cover letters (350)
Southern California (1465)
Startups (3574)
United States (15187)
Vaccines (565)
Weight loss (184)
Date
Last 7 days (583)
Last 30 days (2263)
Last 365 days (35278)
2024 (35118)
2023 (40192)
2022 (51333)
2021 (55890)
2020 (54329)
2019 (46893)
2018 (35290)
2017 (32374)
2016 (31741)
2015 (37804)
2014 (31540)
2013 (26608)
2012 (28786)
2011 (29490)
2010 (27509)
Location
Africa (726)
Arizona (195)
Asia (37650)
Australia (6254)
California (3819)
Canada (1449)
China (305)
Colorado (171)
Connecticut (176)
Europe (81508)
Florida (533)
Georgia (142)
Illinois (386)
Indiana (224)
Maryland (629)
Massachusetts (2962)
Michigan (173)
Minnesota (295)
New Jersey (1105)
New York (1080)
North Carolina (745)
Northern California (1696)
Ohio (147)
Pennsylvania (923)
South America (1094)
Southern California (1465)
Texas (548)
Utah (108)
Washington State (399)
692,037 Results for "aribio usa inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Adaptive Research Announces it has Begun Enrolling Patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial
September 30, 2024
·
3 min read
BioMidwest
AriBio Co., Ltd. Announces Strategic Collaboration with Kentucky Clinical Trial Laboratory (KCTL) to Expand Alzheimer’s Disease Testing
AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.
June 21, 2024
·
3 min read
Drug Development
AriBio Receives IND Approval from China’s NMPA for POLARIS-AD, a Phase 3 Trial for the Treatment of Early Alzheimer’s Disease
AriBio Co., Ltd. (AriBio) announces approval of the Investigational New Drug (IND) application by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the initiation of the Phase 3 Polaris-AD trial in China of AR1001 in early Alzheimer’s Disease (AD) on May 11th, 2024.
May 14, 2024
·
3 min read
Drug Development
AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China for $770 Million USD
AriBio Co., Ltd., announces signing of exclusive marketing rights for AR1001, an investigational drug for early Alzheimer’s disease, in China for up to $770 million USD.
March 24, 2024
·
2 min read
Drug Development
AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
AriBio Co., Ltd. announced authorisation from the European Medicines Agency for POLARIS-AD, a global, phase 3, early Alzheimer’s disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency on the Clinical Trial Authorisation of POLARIS-AD.
April 28, 2024
·
3 min read
Press Releases
Christina Iskandar has been appointed as associate director of human resources at GC Biopharma USA Inc.
November 25, 2024
·
2 min read
Drug Development
MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd.
AriBio Co., Ltd. receives Notice of Acceptance for POLARIS-AD, a Phase 3 early Alzheimer’s disease clinical trial from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom.
February 25, 2024
·
2 min read
Business
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
Coya Therapeutics, Inc. announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024.
May 28, 2024
·
6 min read
Business
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
Collegium Pharmaceutical, Inc. today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta ® ER.
April 29, 2024
·
4 min read
Drug Development
First Participants Enrolled in the AriBio USA Phase 3 Registration Trial to Evaluate AR1001 in Early Alzheimer’s Disease
AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer’s Disease (AD).
January 5, 2023
·
2 min read
1 of 69,204
Next
